Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Esbriet

Chemical Namepirfenidone
Dosage FormCapsule (oral; 267 mg); Tablet (oral; 267 mg, 801 mg)
Drug ClassMiscellaneous
SystemRespiratory
CompanyGenentech
Approval Year2014

Indication

  • For the treatment of idiopathic pulmonary fibrosis (IPF).
Last updated on 7/13/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Esbriet (pirfenidone) Prescribing Information.2022Genentech USA, Inc., South San Francisco, CA
Document TitleYearSource
Pirfenidone for treating idiopathic pulmonary fibrosis. 2018NICE
Document TitleYearSource
Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.2021Chest
Systematic review and meta-analysis of pirfenidone, nintedanib, and pamrevlumab for the treatment of idiopathic pulmonary fibrosis.2021Annals of Pharmacotherapy
Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis.2019Journal of Drug Assessment
Systematic review and network meta-analysis of idiopathic pulmonary fibrosis treatments.2017Journal of Managed care and Specialty Pharmacy
Document TitleYearSource
Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults.2022American Journal of Respiratory and Critical Care Medicine
German guideline for idiopathic pulmonary fibrosis - update on pharmacological therapies 2017.2018Pneumologie (Stuttgart, Germany)